Propentofylline

Propentofylline (HWA 285) is a xanthine derivative with purported neuroprotective effects.

Propentofylline

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	N06BC02 (WHO) QC04AD90 (WHO)
Identifiers
IUPAC name 3-methyl-1-(5-oxohexyl)-7-propyl-3,7-dihydro-1H-purine-2,6-dione
CAS Number	55242-55-2
PubChem CID	4938
ChemSpider	4769
UNII	5RTA398U4H
CompTox Dashboard (EPA)	DTXSID4045189
ECHA InfoCard	100.133.568
Chemical and physical data
Formula	C15H22N4O3
Molar mass	306.366 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CCCn1cnc2c1c(=O)n(c(=O)n2C)CCCCC(=O)C
InChI InChI=1S/C15H22N4O3/c1-4-8-18-10-16-13-12(18)14(21)19(15(22)17(13)3)9-6-5-7-11(2)20/h10H,4-9H2,1-3H3 Key:RBQOQRRFDPXAGN-UHFFFAOYSA-N
(verify)

Pharmacology

It is a phosphodiesterase inhibitor.[1]

It also acts as an adenosine reuptake inhibitor.[1][2][3]

Uses

It was studied as a possible treatment for Alzheimer's disease and multi-infarct dementia.[4][5]

Propentofylline has also been studied, to a lesser extent, as a possible adjunct in the treatment of ischemic stroke, due to its vasodilating properties.[6][7]

Propentofylline is in use as a veterinary medicine in older dogs.[8]

See also

• Pentoxifylline

References

1. Frampton M, Harvey RJ, Kirchner V (2003). Frampton MA (ed.). "Propentofylline for dementia". Cochrane Database Syst Rev (2): CD002853. doi:10.1002/14651858.CD002853. PMID 12804440.
2. Salimi S, Fotouhi A, Ghoreishi A, et al. (April 2008). "A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia". Prog. Neuropsychopharmacol. Biol. Psychiatry. 32 (3): 726–732. doi:10.1016/j.pnpbp.2007.11.021. PMID 18096287.
3. Numagami Y, Marro PJ, Mishra OP, Delivoria-Papadopoulos M (June 1998). "Effect of propentofylline on free radical generation during cerebral hypoxia in the newborn piglet". Neuroscience. 84 (4): 1127–1133. doi:10.1016/S0306-4522(97)00542-3. PMID 9578400.
4. Frampton M, Harvey RJ, Kirchner V (2003). Frampton MA (ed.). "Propentofylline for dementia". Cochrane Database of Systematic Reviews (2): CD002853. doi:10.1002/14651858.CD002853. PMID 12804440.
5. Kittner B, Rössner M, Rother M (1997). "Clinical trials in dementia with propentofylline". Ann. N. Y. Acad. Sci. 826: 307–316. doi:10.1111/j.1749-6632.1997.tb48481.x. PMID 9329701.
6. Bath PM, Bath-Hextall FJ (2004). Bath PM (ed.). "Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke". Cochrane Database of Systematic Reviews (3): CD000162. doi:10.1002/14651858.CD000162.pub2. PMID 15266424.
7. Huber M, Kittner B, Hojer C, Fink GR, Neveling M, Heiss WD (1993). "Effect of propentofylline on regional cerebral glucose metabolism in acute ischemic stroke". J. Cereb. Blood Flow Metab. 13 (3): 526–30. doi:10.1038/jcbfm.1993.68. PMID 8478410.
8. "Launch of tablet to make life easier for dogs in old age". Yorkshire Post. 7 September 2012. Retrieved 28 December 2019.